Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 106

1.

Metastatic melanoma patient had complete response with clonal expansion after whole brain radiation and PD-1 blockade.

Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A.

Cancer Immunol Res. 2017 Jan 6. pii: canimm.0223.2016. doi: 10.1158/2326-6066.CIR-16-0223. [Epub ahead of print]

PMID:
28062513
2.

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.

Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA.

Cancer. 2016 Dec 2. doi: 10.1002/cncr.30463. [Epub ahead of print]

PMID:
27911979
3.

Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (γδ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous γδ T-Cell Lymphomas.

Merrill ED, Agbay R, Miranda RN, Aung PP, Tetzlaff MT, Young KH, Curry JL, Nagarajan P, Ivan D, Prieto VG, Medeiros LJ, Duvic M, Torres-Cabala CA.

Am J Surg Pathol. 2017 Feb;41(2):204-215. doi: 10.1097/PAS.0000000000000768.

PMID:
27879514
4.

Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases.

Nagarajan P, Curry JL, Ning J, Piao J, Torres Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto V, Tetzlaff MT.

Clin Cancer Res. 2016 Nov 18. pii: clincanres.2126.2016. [Epub ahead of print]

PMID:
27864417
5.

Significance of epidermal mitoses in challenging melanocytic proliferations.

Minca EC, Billings SD, Elson P, Tetzlaff MT, Andea AA, Ko JS.

J Cutan Pathol. 2017 Feb;44(2):135-143. doi: 10.1111/cup.12855.

PMID:
27862191
6.

Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.

Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG.

J Cutan Pathol. 2017 Feb;44(2):158-176. doi: 10.1111/cup.12858. Review.

PMID:
27859479
7.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE.

BMC Med. 2016 Oct 25;14(1):168.

8.

High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.

Chakravarti N, Ivan D, Trinh VA, Glitza IC, Curry JL, Torres-Cabala C, Tetzlaff MT, Bassett RL, Prieto VG, Hwu WJ.

Melanoma Res. 2017 Feb;27(1):24-31. doi: 10.1097/CMR.0000000000000305.

PMID:
27768639
9.

Concomitant Cutaneous Langerhans Cell Hystiocytosis and Leukemia Cutis.

Pina-Oviedo S, Torres-Cabala CA, Miranda RN, Tetzlaff MT, Singh S, Rapini RP, Prieto VG, Aung PP.

Am J Dermatopathol. 2016 Oct 18. [Epub ahead of print]

PMID:
27759701
10.

Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case.

Pandey P, Al-Rohil RN, Goldstein JB, Tetzlaff MT, Barnes TG, Baldwin SE, Fogelman D, Abraham SC, Piha-Paul SA.

Am J Dermatopathol. 2016 Nov;38(11):852-856.

PMID:
27043340
11.

Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.

Siroy AE, Aung PP, Torres-Cabala CA, Tetzlaff MT, Nagarajan P, Milton DR, Curry JL, Ivan D, Prieto VG.

Hum Pathol. 2017 Jan;59:48-54. doi: 10.1016/j.humpath.2016.09.010.

PMID:
27666765
12.

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Uemura M, Faisal F, Haymaker C, McQuail N, Sirmans E, Hudgens CW, Barbara L, Bernatchez C, Curry JL, Hwu P, Tetzlaff MT, Diab A.

J Immunother Cancer. 2016 Sep 20;4:55. doi: 10.1186/s40425-016-0157-6.

13.

Living on the Edge: Diagnosing Sarcomatoid Melanoma Using Histopathologic Cues at the Edge of a Dedifferentiated Tumor: A Report of 2 Cases and Review of the Literature.

Erstine EM, Tetzlaff MT, Ko JS, Prieto VG, Cheah AL, Billings SD.

Am J Dermatopathol. 2016 Sep 19. [Epub ahead of print]

PMID:
27655123
14.

Detection of Merkel Cell Polyoma Virus and Beta Human Papillomavirus in Multiple Eccrine Poromas in a Patient With Acute Leukemia Treated With Stem Cell Transplant.

Aung PP, Rady PL, Nagarajan P, Ivan D, Tetzlaff MT, Curry JL, Tyring SK, Prieto VG, Torres-Cabala CA.

Am J Dermatopathol. 2016 Sep 19. [Epub ahead of print] No abstract available.

PMID:
27655121
15.

Primary Cutaneous Gamma-Delta (γ/δ) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings.

Ramani NS, Curry JL, Merrill ED, Aung PP, Prieto V, Tetzlaff MT, Duvic M, Miranda R, Torres-Cabala C.

Am J Dermatopathol. 2016 Oct;38(10):e147-9. doi: 10.1097/DAD.0000000000000608.

PMID:
27533072
16.

Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.

Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP.

J Cutan Pathol. 2016 Dec;43(12):1161-1166. doi: 10.1111/cup.12797.

PMID:
27531242
17.

Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a case.

Honarpisheh HH, Curry JL, Richards K, Nagarajan P, Aung PP, Torres-Cabala CA, Ivan D, Drucker CR, Cartun R, Prieto VG, Tetzlaff MT.

J Cutan Pathol. 2016 Dec;43(12):1155-1160. doi: 10.1111/cup.12792.

PMID:
27516534
18.

Primary cutaneous CD30(+) lymphoproliferative disorders.

Wieser I, Tetzlaff MT, Torres Cabala CA, Duvic M.

J Dtsch Dermatol Ges. 2016 Aug;14(8):767-82. doi: 10.1111/ddg.13117.

PMID:
27509411
19.

Primär kutane CD30(+) lymphoproliferative Erkrankungen.

Wieser I, Tetzlaff MT, Cabala CA, Duvic M.

J Dtsch Dermatol Ges. 2016 Aug;14(8):767-84. doi: 10.1111/ddg.13117_g.

PMID:
27509410
20.

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Sep 8;537(7619):254. doi: 10.1038/nature18939. No abstract available.

PMID:
27383789
Items per page

Supplemental Content

Loading ...
Support Center